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Abstract
Background: Ovarian function suppression (OFS) has been shown to be effective as adjuvant endocrine therapy in
premenopausal women with hormone receptor-positive breast cancer. However, it is currently unclear if addition of
OFS to standard tamoxifen therapy after completion of adjuvant chemotherapy results in a survival benefit. In 2008,
the Korean Breast Cancer Society Study Group initiated the ASTRRA randomized phase III trial to evaluate the
efficacy of OFS in addition to standard tamoxifen treatment in hormone receptor-positive breast cancer patients
who remain or regain premenopausal status after chemotherapy.
Methods: Premenopausal women with estrogen receptor-positive breast cancer treated with definitive surgery
were enrolled after completion of neoadjuvant or adjuvant chemotherapy. Ovarian function was assessed at the
time of enrollment and every 6 months for 2 years by follicular-stimulating hormone levels and bleeding history. If
ovarian function was confirmed as premenopausal status, the patient was randomized to receive 2 years of
goserelin plus 5 years of tamoxifen treatment or 5 years of tamoxifen alone. The primary end point will be the
comparison of the 5-year disease-free survival rates between the OFS and tamoxifen alone groups. Patient
recruitment was finished on March 2014 with the inclusion of a total of 1483 patients. The interim analysis will be
performed at the time of the observation of the 187th event.
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Discussion: This study will provide evidence of the benefit of OFS plus tamoxifen compared with tamoxifen only in
premenopausal patients with estrogen receptor-positive breast cancer treated with chemotherapy.
Trial registration: ClinicalTrials.gov Identifier NCT00912548. Registered May 31 2009. Korean Breast Cancer Society
Study Group Register KBCSG005. Registered October 26 2009.
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Background
Many prospective randomized trials have shown that ad-
juvant endocrine therapy, such as with tamoxifen or
ovarian function suppression (OFS), provides a disease
free survival benefit for young patients with hormone
receptor-positive breast cancer [1–3]. However, there is
insufficient information whether adding OFS to standard
tamoxifen treatment for premenopausal patients is an ef-
fective therapy in reducing disease recurrence.
Premenopausal breast cancer patients with hormone
receptor-positive disease have a worse prognosis than
postmenopausal breast cancer patients with hormone
receptor-positive disease [4, 5]. This difference in sur-
vival may be due to tamoxifen resistance in premeno-
pausal women [5]. Theoretically, the combination of
OFS and tamoxifen therapy could overcome tamoxifen
resistance in premenopausal women. However, in the
absence of clinical evidence of a definitive survival bene-
fit associated with OFS plus standard tamoxifen therapy,
additional toxicities from OFS treatment complicate rec-
ommendation of this treatment regimen. Therefore, it is
important to identify patients most likely to benefit from
additional OFS treatment.
The results of the Suppression of Ovarian Function
Trial (SOFT), a randomized, phase 3 trial conducted by
The International Breast Cancer Study Group (IBCSG),
showed no significant benefit from the addition of ovar-
ian suppression to tamoxifen in overall patients [6].
However, in women who remained premenopausal and
were at sufficient risk of recurrence to warrant adjuvant
chemotherapy, the addition of OFS improved disease
outcomes. In SOFT, ovarian function was assessed by
serum E2 measurement just one time within 8 months
after chemotherapy regardless of menstruation. How-
ever, it is assumed that examination at only one time
point may be insufficient to evaluate ovarian function
after chemotherapy. The patients who regain ovarian
function later may lose the chance to benefit from the
addition of ovarian suppression treatment. The patients
who regain ovarian function later may lose their chance
to benefit from the addition of ovarian suppression treat-
ment. As there is no standard method to predict the re-
sumption of ovarian function at the time of chemotherapy
completion, we decided to evaluate ovarian function re-
peatedly for 2 years.
The Korean Breast Cancer Society Study Group has
designed and initiated a randomized phase III trial com-
paring OFS plus tamoxifen versus tamoxifen only after
chemotherapy in young women with estrogen receptor-
positive breast cancer (ASTRRA); participants include
those with premenopausal status or those who have
regained ovarian function after the completion of neoad-
juvant or adjuvant chemotherapy. The primary objective
of this study is to compare the 5-year disease-free sur-
vival rates between the two groups.
Methods/design
Study design and setting
ASTRRA is a phase III open-label, prospective, random-
ized, multicenter investigator initiated clinical trial. The
trial was designed to evaluate the combination of 2 years
of goserelin plus 5 years of tamoxifen (OFS group) ver-
sus 5 years of tamoxifen alone (tamoxifen alone group)
as adjuvant endocrine therapy according to ovarian
function after the completion of neoadjuvant or adju-
vant chemotherapy in patients with estrogen receptor-
positive breast cancer. The Korean Breast Cancer Society
Study Group coordinates the trial, and the Steering Com-
mittee oversees the trial. The institutional review board of
Korea Cancer Center Hospital was approved the protocol
version 1.3 [K-0902-004-009]. The study protocol was
approved by each institutional review board of all partici-
pating centers as well. Table 1 shows the list of participat-
ing centers. All patients provided written informed
consent before enrollment.
Patients
The trial enrolled premenopausal women ≤ 45 years of
age with histologically confirmed estrogen receptor-
positive, stage I–III, primary invasive breast cancer
treated with definitive surgery and chemotherapy. Pre-
menopausal status for inclusion criteria was defined as
having a regular menstruation history at the time of
diagnosis. Estrogen receptor positivity was determined
as expression of estrogen receptor in at least 10 % of
tumor cells as determined by immunohistochemistry or
10 fmol/mg cytosol protein as determined by a dextran-
coated charcoal ligand binding assay.
Receipt of neoadjuvant or adjuvant chemotherapy was
required, and the standard regimens were allowed except
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CMF. Adjuvant trastuzumab therapy for patients with
human epidermal growth factor receptor-2-positive dis-
ease was permitted, although it was not considered as
chemotherapy.
We excluded patients with other primary malignancies
within the last 5 years, except for adequately treated in
situ carcinoma of the cervix, basal cell carcinoma, or
squamous cell carcinoma of the skin. In addition, pa-
tients with thrombocytopenia, those currently treated
with anti-coagulant agents, and patients that were preg-
nant, lactating, or treated with investigational drugs
within the previous 4 weeks before baseline assessment
were excluded.
Study design
The first screening test to evaluate ovarian function was
performed within 3 months of the final dose of chemo-
therapy. Premenopausal status at the first screening test
was defined by serum follicular stimulating hormone
(FSH) levels < 30 mIU/ml. At 6, 12, 18, and 24 months
following the baseline assessment, ovarian function sta-
tus is to be evaluated by menstruation status and serum
FSH levels. Regaining premenopausal status is defined
by FSH levels < 30mIU/ml or bleeding history within
6 months of each visit. Study visits will be every
6 months for 5 years and at least yearly thereafter, ac-
cording to each institute’s routine practice. If the patient
does not regain satisfy the definition of being premeno-
pausal during the 24 months after enrollment, the pa-
tient will be categorized to the permanent menopause
group (group A). At each visit, newly confirmed pre-
menopausal patients will be randomly assigned in a 1:1
ratio to the OFS group (group C or group E) or the tam-
oxifen alone group (group B or group D). The OFS
group is treated with 3.6 mg subcutaneous injection
goserelin (Zoladex® [D-Ser(But)6 Azgly10 luteinizing-
hormone-releasing hormone]; AstraZeneca) every
28 days for 2 years plus oral tamoxifen at a dose of
20 mg daily for 5 years. The tamoxifen only group is
treated with oral tamoxifen at a dose of 20 mg daily for
5 years. Randomization is performed by means of an
internet-based system and is stratified according to
lymph node status (negative versus positive) and insti-
tutes (Fig. 1). Data are collected and stored in a digital
case report form.
Primary and secondary end points
The primary end point is to compare the 5-year disease-
free survival rates between the OFS and tamoxifen alone
groups, particularly among patients with premenopausal
status (assessed every 6 months for 2 years) after the
completion of chemotherapy. Disease-free survival is de-
fined as the time from enrollment to the detection of in-
vasive recurrence of breast cancer (local, regional, or
distant metastasis), contralateral breast cancer, second-
ary malignancy, or death without breast cancer recur-
rence. Patients who are still alive without any event at
the time of the analysis will be censored.
Secondary end points are (1) to compare overall sur-
vival rates between groups, (2) to compare 5-year
Table 1 List of participating centers of ASTRRA trial
Names of institutes
Ajou University, School of Medicine
Cheil General Hospital and Women’s Healthcare Center, Dankook
University College of Medicine
Chonbuk National University Medical School
Chonnam National University Hwasun Hospital
Chungnam National University Hospital
Chungbuk National University College of Medicine and Medical
Research Institute
Daejeon St. Mary’s Hospital, The Catholic University of Korea
Dong-A University Hospital
Eulji University Hospital
Gachon University Gil Hospital
Gangnam Severance Hospital, Yonsei University
Hallym University Sacred Heart Hospital, College of Medicine, Hallym
University
Inha University Hospital, Inha University
Inje University Busan Paik Hospital
Inje University Sanggye Paik Hospital, Inje University College of Medicine
KangDong sacred heart hospital, Hallym university
Kangseo Mizmedi Hospital
Keimyung University School of Medicine
Konkuk University School of Medicine
Korea Cancer Center Hospital, Korea Institute of Radiological and
Medical Sciences
Korea University Anam Hospital
Mokdong Hospital, Ewha Womans University
Myongji Hospital
National Cancer Center
Samsung Medical Center, Sungkyunkwan University School of medicine
Seoul National University Boramae Medical Center
Seoul National University Hospital, Seoul National University College of
Medicine
Seoul St. Mary’s Hospital, Medical College of The Catholic University of Korea
Soonchunhyang University College of Medicine, Cheonan Hospital
Soonchunhyang University Colleage of Medicine
Soonchunhyang University College of Medicine, Bucheon Hospital
Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital
University of Ulsan, Asan Medical Center
Yeungnam University Hospital
Yonsei University College of Medicine
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disease-free survival rates between postmenopausal pa-
tients treated with tamoxifen and premenopausal pa-
tients treated with OFS plus tamoxifen, (3) to determine
the tolerability of tamoxifen with or without goserelin.
Sample size calculation and statistics
Planned enrollment was at least 1234 patients. Initially,
the design projected that 2 years of accrual, plus 5 years
of additional follow-up would be sufficient to observe
the target of 374 disease-free survival events across the
two treatment arms, with 85 % power to detect 7 % re-
duction in hazard with OFS plus tamoxifen versus tam-
oxifen alone. In 2010, because of a slower-than-expected
enrollment rate, the steering committee extended the ac-
crual period from 2 years to 4 years.
An intent-to-treatment analysis and per-protocol ana-
lysis will be performed. The disease-free survival rate
will be evaluated using the Kaplan-Meier method. The
log-rank test will be used to compare the treatment
groups. Multivariate analyses will be performed using
Cox’s proportional hazards model.
Trial progress
Recruitment was closed on March 2014. Between March
2009 and March 2014, 1485 patients were screened, and
1483 patients from 35 institutes in South Korea were en-
rolled in this study. On January 12 2015, 634 patients
were randomized to the OFS group, and 655 patients
were randomized to the tamoxifen only group (Table 2).
Eighty patients were classified as permanent menopause
status. Another 114 patients continue to exhibit a status
of chemotherapy-induced amenorrhea, and the ovarian
function of these patients is being evaluated every
6 months. All of the patients received chemotherapy be-
fore randomization. Node-positive disease was present
in 56.3 % of the patients. The first interim analysis will
be performed when 50 % of the planned disease-free sur-
vival events (187 events) have occurred.
Discussion
In South Korea, 48.7 % of newly diagnosed breast cancer
patients in 2011 were premenopausal and less than
50 years of age [7]. Although the total number of pa-
tients is smaller than that of western countries, the rate
of premenopausal patients is higher in South Korea. The
Korean Breast Cancer Society has been focused on
developing optimal tailored therapy for these patients
because of the relatively higher proportion of premeno-
pausal patients in the Korean breast cancer patient
population. In 2008, the Korean Breast Cancer Society
Study Group initiated the ASTRRA trial to answer the
following questions: (1) whether disease free survival
benefits could be achieved with the addition of OFS to
standard 5-year tamoxifen treatment after the com-
pletion of neoadjuvant or adjuvant chemotherapy in
premenopausal young women with estrogen receptor-
positive disease, and (2) whether delayed OFS treatment
could reduce disease recurrence in patients with recov-
ered ovarian function who experienced chemotherapy-
induced amenorrhea and who were treated with stand-
ard tamoxifen therapy.
Results from phase III trials including OFS, as well as
a meta-analysis of these trials, might help to advance
current knowledge of the survival advantage gained with
addition of OFS treatment [8–14]. Of these trials, SOFT
was a randomized, three-arm, phase III trial designed to
investigate the role of OFS in women with premeno-
pausal status either after completion of (neo)adjuvant
chemotherapy or following surgery alone. The SOFT
trial included three arms: (1) tamoxifen only for 5 years,
Fig. 1 Study design
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(2) tamoxifen for 5 years + OFS for 5 years, and (3) exe-
mestane for 5 years + OFS for 5 years [15]. One of the
comparisons in the SOFT trial was tamoxifen + OFS ver-
sus tamoxifen alone, similar to the comparison in the
ASTRRA trial. Although the studies have some resem-
blance, there are significant distinctions between the
study design of the SOFT trial and the ASTRRA trial.
First, the ASTRRA trial has only included women aged ≤
45 years. Because standard endocrine therapy takes at
least 5 years, older premenopausal women could experi-
ence natural, spontaneous menopause during endocrine
therapy, and this would obscure the effect of OFS. Sec-
ond, in contrast to the SOFT trial population, only 53 %
of which were treated with chemotherapy, all partici-
pants in the ASTRRA trial received neoadjuvant or adju-
vant chemotherapy before enrollment. Thus, ASTRRA
trial focuses more on the role of OFS after completing
chemotherapy. Third, ovarian function was assessed only
one time (based on estradiol levels) at the time of
randomization in the SOFT trial, within 8 months after
completing chemotheapy. However, resumption of ovar-
ian function occurs in about 60 % of women younger
than 45 years of age within 2 years after completing
chemotherapy [16, 17]. We assume that patients who re-
cently regained ovarian function may lose the chance to
benefit from the addition of OFS treatment. Therefore,
Table 2 Demographics of randomized patients
Tamoxifen only group (B +D group, N= 655) Ovarian function suppression group
(C + E group, N= 634)
P-value
Age(mean, years) 39.7 ± 4.1 39.6 ± 4.1 0.580
Stage
I 178 (27.2 %) 169 (26.7 %) 0.977
II 335 (51.1 %) 332 (52.4 %)
III 121 (18.5 %) 113 (17.8 %)
Unidentified 21 (3.2 %) 20 (3.2 %)
Lymph node status
Negative 279 (42.6 %) 275 (43.4 %) 0.927
Positive 371 (56.6 %) 355 (56.0 %)
Unidentified 5 (0.8 %) 4 (0.6 %)
Histology
Invasive ductal carcinoma 573 (87.5 %) 560 (88.3 %) 0.917
Invasive lobular carcinoma 32 (4.9 %) 26 (4.1 %)
Others 42 (6.4 %) 41 (6.5 %)
Unidentified 8 (1.2 %) 7 (1.1 %)
Histologic grade
G1 95(14.5 %) 118 (18.6 %) 0.229
G2 359 (54.8 %) 323 (50.9 %)
G3 160 (24.4 %) 151 (23.8 %)
Unidentified 41(6.3 %) 42 (6.6 %)
Chemotherapy regimen
Anthracycline + cyclophosphamide 184 (28.1 %) 185 (29.2 %) 0.782
Anthracycline + cyclophosphamide followed by taxane 324 (49.5 %) 318 (50.2 %)
Anthracycline + taxane 30 (4.6 %) 29 (4.6 %)
5-fluorouracil + anthracycline + cyclophosphamide 74 (11.3 %) 73(11.5 %)
Others 21 (3.2 %) 14(2.2 %)
Unidentified 22 (3.4 %) 15 (2.4 %)
Operation
Total mastectomy 268 (40.9 %) 248 (39.1 %) 0.762
Breast conserving surgery 382 (58.3 %) 382 (60.3 %)
Unidentified 5 (0.8 %) 4 (0.6 %)
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in the ASTRRA trial, ovarian function will be evaluated
by menstruation history or FSH levels every 6 months
from the time of enrollment for at least 2 years. Until
now, 1286 (86.7 %) patients in the ASTRRA trial are
premenopausal or have regained premenopausal status
after chemotherapy, and only 80 (5.4 %) patients have
been classified to the permanent menopausal group after
2 years of observation. Examination at only one time
point may thus be insufficient to evaluate ovarian func-
tion after chemotherapy.
The proportion of patients with regained ovarian func-
tion is slightly higher in the ASTRRA trial than in other
reports. This might be caused by the exclusion of pa-
tients treated with CMF regimens [16, 17]. Because most
patients treated with CMF do not recover from
chemotherapy-induced amenorrhea, we excluded pa-
tients who had received the CMF regimen [8, 16, 17]. In
contrast to the CMF regimen, modern non-CMF chemo-
therapy regimens result in less permanent amenorrhea
after treatment. The NSABP B-30 trial assessed men-
strual status after various non-CMF chemotherapy regi-
mens at baseline and every 6 months over 24 months.
The incidence of amenorrhea 12 months after random
assignment was 69.8 % for sequential doxorubicin and
cyclophosphamide followed by docetaxel, 57.7 % for con-
current docetaxel-doxorubicin-cyclophosphamide, and
37.9 % for concurrent docetaxel-doxorubicin (P < 0.001)
[18]. Although CMF is an effective chemotherapy regimen
for breast cancer patients, use of the CMF regimen in
young patients is currently decreasing in South Korea.
Thus, we believe that the removal of the CMF regimen
from the trial’s acceptable chemotherapy regimen list is
compatible with recent trends in the care of young women
with breast cancer. Another reason for the high rate of
ovarian function resumption in the ASTRRA trial would
be the relatively young age of participants. The NSABP B-
30 trial showed that age is significantly related to the inci-
dence of chemotherapy-induced amenorrhea [18].
The important advantage of the ASTRRA trial study de-
sign is the repeated evaluation of ovarian function. The
longitudinal evaluation of ovarian function may help to se-
lect the most appropriate patients to receive additional
OFS treatment, thereby avoiding unnecessary side effects.
OFS causes menopausal symptoms and bone mass loss
[19, 20]; menopausal symptoms, such as vasomotor symp-
toms, vaginal dryness, vaginal discharge, anxiety, depres-
sion, or sleep disturbances, significantly affect quality of
life [19]. Sometimes these symptoms result in low compli-
ance or destroy the physician-patient relationship. Because
there is yet no reliable biomarker to select patients most
likely to benefit from OFS, continuous checking of ovarian
function may facilitate this patient selection.
Currently, the ASTRRA trial has closed to accrual, with
a total 1483 enrolled patients. Through the ASTRRA trial,
we can determine optimal endocrine therapy based on
real-time ovarian function status for each premenopausal
breast cancer patient with estrogen receptor-positive dis-
ease who received neoadjuvant or adjuvant chemotherapy.
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